CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling.
Saved in:
| Title: | CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling. |
|---|---|
| Authors: | Fix SM; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Forget MA; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Sakellariou-Thompson D; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Wang Y; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Griffiths TM; Biologics Development, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Lee M; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Haymaker CL; Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Dominguez AL; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Basar R; Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Reyes C; Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA., Kumar S; Cell Biology R&D, Thermo Fisher Scientific, Carlsbad, California, USA., Meyer LA; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Hwu P; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA Patrick.Hwu@moffitt.org., Bernatchez C; Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Jazaeri AA; Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2022 Jul; Vol. 10 (7). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Print Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
